Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Andrea R. Menicucci"'
Autor:
Andrea Marzi, Allen Jankeel, Andrea R. Menicucci, Julie Callison, Kyle L. O’Donnell, Friederike Feldmann, Amanda N. Pinski, Patrick W. Hanley, Ilhem Messaoudi
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Marburg virus (MARV) is a member of the filovirus family that causes hemorrhagic disease with high case fatality rates. MARV is on the priority list of the World Health Organization for countermeasure development highlighting its potential impact on
Externí odkaz:
https://doaj.org/article/517ce9348a0142e6a98fc9c7faa08a84
Autor:
Courtney Woolsey, Andrea R. Menicucci, Robert W. Cross, Priya Luthra, Krystle N. Agans, Viktoriya Borisevich, Joan B. Geisbert, Chad E. Mire, Karla A. Fenton, Allen Jankeel, Sneha Anand, Hideki Ebihara, Thomas W. Geisbert, Ilhem Messaoudi, Christopher F. Basler
Publikováno v:
Cell Reports, Vol 28, Iss 12, Pp 3032-3046.e6 (2019)
Summary: Zaire ebolavirus (EBOV) VP35 protein is a suppressor of type I interferon (IFN) production, an inhibitor of dendritic cell maturation, and a putative virulence determinant. Here, a recombinant EBOV encoding a mutant VP35 virus (VP35m) is dem
Externí odkaz:
https://doaj.org/article/fe494133553a485dafbc2ad2bd373312
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Ebola virus (EBOV) poses a significant threat to human health as highlighted by the recent epidemic in West Africa. Data from animal studies and a ring vaccination clinical trial conducted in Guinea during the recent epidemic demonstrated th
Externí odkaz:
https://doaj.org/article/4b77c33de9834ef5828488469523c3c1
Publikováno v:
mBio, Vol 10, Iss 3 (2019)
ABSTRACT Ebola virus (EBOV) is a single-stranded RNA virus that causes Ebola virus disease (EVD), characterized by excessive inflammation, lymphocyte apoptosis, hemorrhage, and coagulation defects leading to multiorgan failure and shock. Recombinant
Externí odkaz:
https://doaj.org/article/22b8b5e8b08d41a8839aae168a0e384a
Autor:
Andrea Marzi, Andrea R. Menicucci, Flora Engelmann, Julie Callison, Eva J. Horne, Friederike Feldmann, Allen Jankeel, Heinz Feldmann, Ilhem Messaoudi
Publikováno v:
Frontiers in Immunology, Vol 9 (2019)
Marburg virus (MARV) is the causative agent of hemorrhagic fever outbreaks with high case fatality rates. Closely related to Ebola virus, MARV is a filamentous virus with a negative-sense, single-stranded RNA genome. Although extensive studies on fil
Externí odkaz:
https://doaj.org/article/d934c5812845498ea500e398a516c0b2
Autor:
Andrea R. Menicucci, Krista Versteeg, Courtney Woolsey, Chad E. Mire, Joan B. Geisbert, Robert W. Cross, Krystle N. Agans, Allen Jankeel, Thomas W. Geisbert, Ilhem Messaoudi
Publikováno v:
Frontiers in Immunology, Vol 8 (2017)
Existing models of Ebola virus disease (EVD) suggest antigen-presenting cells are initial targets of Zaire ebolavirus (ZEBOV). In vitro studies have shown that ZEBOV infection of monocytes and macrophages results in the production of inflammatory med
Externí odkaz:
https://doaj.org/article/65eb4dc7b0a94eaaabaf314c8b6936b4
Autor:
Midas M. Kuilman, Architha Ellappalayam, Andrei Barcaru, Josien C. Haan, Rajith Bhaskaran, Diederik Wehkamp, Andrea R. Menicucci, William M. Audeh, Lorenza Mittempergher, Annuska M. Glas
Publikováno v:
Breast Cancer Research and Treatment. 195:263-274
Purpose BluePrint (BP) is an 80-gene molecular subtyping test that classifies early-stage breast cancer (EBC) into Basal, Luminal, and HER2 subtypes. In most cases, breast tumors have one dominant subtype, representative of a single activated pathway
Autor:
Pat W. Whitworth, Peter D. Beitsch, Mary K. Murray, Paul D. Richards, Angela Mislowsky, Carrie L. Dul, James V. Pellicane, Paul L. Baron, Rakhshanda Layeequr Rahman, Laura A. Lee, Beth B. Dupree, Pond R. Kelemen, Andrew Y. Ashikari, Raye J. Budway, Cristina Lopez-Penalver, William Dooley, Shiyu Wang, Patricia Dauer, Andrea R. Menicucci, Erin B. Yoder, Christine Finn, Lisa E. Blumencranz, William Audeh
Publikováno v:
JCO precision oncology. 6
PURPOSE The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete respons
Autor:
James V. Pellicane, Peter D. Beitsch, David T. Rock, Raye J. Budway, Carrie L. Dul, Pond R. Kelemen, Andrew Y. Ashikari, Paul L. Baron, Paul D. Weinstein, Angela Mislowsky, Laura A. Lee, Jennifer Beatty, Mary K. Murray, Beth B. Dupree, Christine Finn, Kate Corcoran, Shiyu Wang, Andrea R. Menicucci, Erin B. Yoder, Lisa E. Blumencranz, Patricia Dauer, William Audeh, Pat W. Whitworth
Publikováno v:
Surgical oncology. 45
As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are likely to benefit from NET. NBRST (NCT01479101) compared the
Autor:
Pat W, Whitworth, Peter D, Beitsch, James V, Pellicane, Paul L, Baron, Laura A, Lee, Carrie L, Dul, Mary K, Murray, Mark A, Gittleman, Raye J, Budway, Rakhshanda Layeequr, Rahman, Pond R, Kelemen, William C, Dooley, David T, Rock, Kenneth H, Cowan, Beth-Ann, Lesnikoski, Julie L, Barone, Andrew Y, Ashikari, Beth B, Dupree, Shiyu, Wang, Andrea R, Menicucci, Erin B, Yoder, Christine, Finn, Kate, Corcoran, Lisa E, Blumencranz, William, Audeh
Publikováno v:
JCO Precision Oncology.
PURPOSE The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor–positive [ER+], human epidermal growth factor receptor 2–negative [HER2–]) as Ba